TABUTEAU HERRIOT sold $11.9M of AXSM
TABUTEAU HERRIOT (Chief Executive Officer) sold 49,666 shares of Axsome Therapeutics, Inc. (AXSM) at $240.25 ($11.93M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete datapoint on insider selling size and execution price, but does not indicate a change in company fundamentals or guidance.
Market read
A single, sizable CEO sale can create short-term sentiment noise, though the 10b5-1 framing typically dampens interpretive impact.
What to watch
Traders may miss that the filing includes holdings after sale (7,229 shares), which helps gauge whether future selling pressure is likely under the same plan.
Background
This is an SEC Form 4 insider transaction (open-market sale) by Axsome Therapeutics’ CEO, executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Axsome Therapeutics CEO TABUTEAU HERRIOT sold 49,666 shares on 2026-07-01 at $240.25/share for ~$11.93M under a 10b5-1 plan.
Likely modest/short-lived sentiment impact; no direct fundamental change implied by the filing alone.
Form 4 discloses transaction size and price, but explicitly notes a pre-arranged 10b5-1 plan, reducing inference about new negative information.
Market effects
Insider-sale disclosure may slightly influence sentiment toward biotech/neurology drug developers, but no sector-wide catalyst is provided.
No clear regional spillover; event is company-specific.
Limited global relevance; transaction is a single-company insider Form 4.
Counterpoint
Because the sale is under a 10b5-1 plan, the market may overreact; the filing could be largely mechanical rather than information-bearing.
Key entities
- issuerAxsome Therapeutics, Inc.
Subject of the Form 4 insider sale; CEO sold 49,666 shares at $240.25/share on 2026-07-01.
- insiderTABUTEAU HERRIOT
CEO/Officer/Director/10% Owner who executed the sale under a 10b5-1 plan.
